MX2011009147A - Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh. - Google Patents
Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh.Info
- Publication number
- MX2011009147A MX2011009147A MX2011009147A MX2011009147A MX2011009147A MX 2011009147 A MX2011009147 A MX 2011009147A MX 2011009147 A MX2011009147 A MX 2011009147A MX 2011009147 A MX2011009147 A MX 2011009147A MX 2011009147 A MX2011009147 A MX 2011009147A
- Authority
- MX
- Mexico
- Prior art keywords
- tromethamine
- addition salts
- acid derivatives
- azabiphenylaminobenzoic acid
- dhodh inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a nuevas sales de adición cristalinas de (i) trometamina con (ii) un derivado de ácido azabifenilaminobenzoico de fórmula (I) (ver fórmula (I)) en la que R1 se selecciona del grupo que consiste en alquilo C1-C4, cicloalquilo C3-C4 y CF3, G1 se selecciona de átomos de nitrógeno y grupos CH, C(CH3) y C(CF3), y G2 representa un grupo fenilo opcionalmente sustituido con uno o dos sustituyentes seleccionados de cloro, fluoro, metoxi, etoxi, isopropoxi, trifluorometoxi, CF3, y CONR7R8, en donde R7 es hidrógeno y R8 es ciclopropilo o R7 y R8 junto con el átomo de nitrógeno al que están unidos forman un grupo de fórmula (ver fórmula) donde n es 1; y sus solvatos farmacéuticamente aceptables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09382032A EP2230232A1 (en) | 2009-03-13 | 2009-03-13 | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
PCT/EP2010/001549 WO2010102825A1 (en) | 2009-03-13 | 2010-03-11 | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011009147A true MX2011009147A (es) | 2011-09-15 |
Family
ID=40671396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011009147A MX2011009147A (es) | 2009-03-13 | 2010-03-11 | Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh. |
Country Status (21)
Country | Link |
---|---|
US (1) | US20120003183A1 (es) |
EP (2) | EP2230232A1 (es) |
JP (1) | JP2012520251A (es) |
KR (1) | KR20110126695A (es) |
CN (1) | CN102341372A (es) |
AR (1) | AR075737A1 (es) |
AU (1) | AU2010223527A1 (es) |
CA (1) | CA2754785A1 (es) |
CL (1) | CL2011002213A1 (es) |
CO (1) | CO6501157A2 (es) |
EA (1) | EA201101298A1 (es) |
EC (1) | ECSP11011384A (es) |
IL (1) | IL214517A0 (es) |
MX (1) | MX2011009147A (es) |
NZ (1) | NZ594491A (es) |
PE (1) | PE20120328A1 (es) |
SG (2) | SG10201400568PA (es) |
TW (1) | TW201033177A (es) |
UY (1) | UY32465A (es) |
WO (1) | WO2010102825A1 (es) |
ZA (1) | ZA201105743B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
EP2135610A1 (en) * | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
CN110903219A (zh) * | 2018-09-18 | 2020-03-24 | 广东东阳光药业有限公司 | 酰胺衍生物的盐及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9804343D0 (en) | 1998-02-27 | 1998-04-22 | Univ Cardiff | Chemical compounds |
EP1935416A3 (en) | 2001-04-05 | 2008-10-22 | Aventis Pharma Inc | (Z) -2-cyano-3-hydroxybut-2-enoic acid (4'-trifluoromethylphenyl) amide for the treatment of multiple sclerosis |
PE20030120A1 (es) * | 2001-06-19 | 2003-02-12 | Merck & Co Inc | Sal amina de un antagonista de receptor de integrin |
WO2003006424A1 (en) | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
EP1581478A1 (en) | 2002-12-23 | 2005-10-05 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
WO2004056746A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
CN1993125A (zh) | 2004-05-21 | 2007-07-04 | Uab研究基金会 | 涉及嘧啶合成抑制剂的组合物和方法 |
WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
CN101043883A (zh) | 2004-10-19 | 2007-09-26 | 安万特药物公司 | (z)-2-氰基-3-羟基-丁-2-烯酸-(4'-三氟甲基苯基)-酰胺用于治疗炎症性肠病的用途 |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
-
2009
- 2009-03-13 EP EP09382032A patent/EP2230232A1/en not_active Withdrawn
-
2010
- 2010-02-24 UY UY0001032465A patent/UY32465A/es unknown
- 2010-03-08 TW TW099106618A patent/TW201033177A/zh unknown
- 2010-03-11 AU AU2010223527A patent/AU2010223527A1/en not_active Abandoned
- 2010-03-11 SG SG10201400568PA patent/SG10201400568PA/en unknown
- 2010-03-11 SG SG2011060829A patent/SG173824A1/en unknown
- 2010-03-11 JP JP2011553359A patent/JP2012520251A/ja active Pending
- 2010-03-11 MX MX2011009147A patent/MX2011009147A/es not_active Application Discontinuation
- 2010-03-11 NZ NZ594491A patent/NZ594491A/xx not_active IP Right Cessation
- 2010-03-11 CN CN2010800108779A patent/CN102341372A/zh active Pending
- 2010-03-11 EP EP10708733A patent/EP2406222A1/en not_active Withdrawn
- 2010-03-11 KR KR1020117021320A patent/KR20110126695A/ko not_active Application Discontinuation
- 2010-03-11 US US13/256,104 patent/US20120003183A1/en not_active Abandoned
- 2010-03-11 AR ARP100100740A patent/AR075737A1/es not_active Application Discontinuation
- 2010-03-11 WO PCT/EP2010/001549 patent/WO2010102825A1/en active Application Filing
- 2010-03-11 CA CA2754785A patent/CA2754785A1/en not_active Abandoned
- 2010-03-11 PE PE2011001597A patent/PE20120328A1/es not_active Application Discontinuation
- 2010-03-11 EA EA201101298A patent/EA201101298A1/ru unknown
-
2011
- 2011-08-04 ZA ZA2011/05743A patent/ZA201105743B/en unknown
- 2011-08-08 IL IL214517A patent/IL214517A0/en unknown
- 2011-09-01 CO CO11112331A patent/CO6501157A2/es active IP Right Grant
- 2011-09-08 CL CL2011002213A patent/CL2011002213A1/es unknown
- 2011-10-07 EC EC2011011384A patent/ECSP11011384A/es unknown
Also Published As
Publication number | Publication date |
---|---|
NZ594491A (en) | 2013-11-29 |
UY32465A (es) | 2010-05-31 |
SG173824A1 (en) | 2011-09-29 |
AU2010223527A1 (en) | 2011-08-25 |
TW201033177A (en) | 2010-09-16 |
ECSP11011384A (es) | 2011-11-30 |
CL2011002213A1 (es) | 2012-03-09 |
EA201101298A1 (ru) | 2012-04-30 |
ZA201105743B (en) | 2012-04-25 |
CA2754785A1 (en) | 2010-09-16 |
JP2012520251A (ja) | 2012-09-06 |
EP2406222A1 (en) | 2012-01-18 |
CO6501157A2 (es) | 2012-08-15 |
KR20110126695A (ko) | 2011-11-23 |
AR075737A1 (es) | 2011-04-20 |
US20120003183A1 (en) | 2012-01-05 |
IL214517A0 (en) | 2011-09-27 |
EP2230232A1 (en) | 2010-09-22 |
PE20120328A1 (es) | 2012-03-29 |
CN102341372A (zh) | 2012-02-01 |
WO2010102825A1 (en) | 2010-09-16 |
SG10201400568PA (en) | 2014-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6261379A2 (es) | Compuestos de ciclopentandiona y derivados utiles como herbicidas | |
EA201591000A1 (ru) | Пирролобензодиазепины | |
MX2011009147A (es) | Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh. | |
ECSP12012212A (es) | Derivados de ariletinilo | |
MX2011007455A (es) | Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1). | |
MX2012015023A (es) | Derivado novedoso de nicotinamida o sal del mismo. | |
RS52166B (en) | AMINO-HETEROCYCLIC COMPOUNDS | |
WO2012003405A4 (en) | Sgc stimulators | |
PH12016502037A1 (en) | Certain amino-pyrimidines, compositions thereof, and methods for their use | |
RS54175B1 (en) | BROMODOMEN INHIBITORS AND THEIR APPLICATION | |
MX2010007833A (es) | Compuestos que tienen actividad antagonista de crth2. | |
RS53451B (en) | INHIBITORI P70 S6 KINAZE | |
MX2012001313A (es) | Compuesto espirociclicos que contienen nitrogeno y su uso medicinal. | |
EA201170096A1 (ru) | Замещенные производные пиримидона | |
WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
MX2011009146A (es) | Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh. | |
MY169179A (en) | Novel piperidine compound or salt thereof | |
UA97821C2 (en) | Cyclized derivatives as eg-5 inhibitors | |
MX360667B (es) | Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
MY159870A (en) | Piperazine compound capable of inhibiting prostaglandin d synthase | |
AR072803A1 (es) | Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes | |
MY165634A (en) | Pyrazole compounds having therapeutic effect on multiple myeloma | |
MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. | |
MX341341B (es) | Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90). | |
MX2011009746A (es) | Derivados de n-[(6-aza-biciclo[3.2.1]oct-5-il)-abril-metil]-hetero benzamida, su prepracion y su uso en terapeutica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |